Hologic stock exits Nasdaq after USD 76 cash deal closes

Published on 09/24/2026 at 11:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hologic stock left Nasdaq on April 7, 2026, after a USD 76.00 cash payment was completed. A contingent value right adds up to USD 3.00 per share.

Fotorealistisches Mammographiegerät in hellem klinischem Untersuchungsraum mit Pflegekraft — Hologic zeigt ein Mammographie Gerät in einem modernen klinischen Untersuchungsraum ISIN US4364401012, Illustration mit AI erstellt.

Hologic stock (ISIN US4364401012) left Nasdaq on April 7, 2026, when the medical technology company completed its take private transaction. Stockholders received USD 76.00 in cash for each share, while a contingent value right could add up to USD 3.00 per share.

Cash payment sets the floor

According to StockTitan, the merger became effective on April 7, 2026. Each Hologic common share was converted into the right to receive USD 76.00 in cash and one contingent value right worth up to an additional USD 3.00 if payable.

The cash component represented 96.2 percent of the maximum USD 79.00 consideration. The CVR represented the remaining 3.8 percent and was tied to future revenue performance in Hologic's breast health business.

Private ownership changes the stock story

Multiples VC states that Blackstone and TPG completed the acquisition at an enterprise value of USD 18.3 billion and that Hologic was officially delisted from Nasdaq after completion. The page describes Hologic as no longer listed, so HOLX is no longer a conventional publicly traded stock as of September 24, 2026.

That distinction matters for investors reviewing old quote pages. Historical references to USD 76.01 or a Nasdaq percentage change do not represent a current exchange price after the April transaction. The remaining economic interest is the potential CVR payment, not an actively traded share position.

Hologic now operates privately

Hologic continues to operate as a women's health and medical technology company after the transaction. Its public website describes operations spanning diagnostics, medical imaging and treatment technologies, while the ownership structure has shifted from public shareholders to private equity sponsors.

Nasdaq listing ended in April

Hologic's public market status ended on April 7, 2026. The documented consideration was USD 76.00 in cash per share, with total potential value capped at USD 79.00 per share through the CVR.